Incorporated in 2009, Embracing Future Holdings Limited (“EFH” or the “Company” and together with its subsidiaries the “Group”) focuses on developing a portfolio of innovative diagnostic solutions to lower healthcare costs and improve clinical outcomes.
To diversify our business model and build long term growth, the Group is also actively exploring technology-enabled lifestyle businesses, which would involve the ownership, operation and management of Multi-Channel Networks (“MCN”) businesses, live streaming social e-commerce platforms and Esports-related businesses.
Biolidics has developed and commercialised the ClearCell® FX1 System, a fully automated IVD medical device which relies on a novel patented technology to separate and enrich cancer cells from blood.
Fully automated and entirely label-free, Biolidics’ ClearCell® FX1 System, with the patented microfluidic biochip, CTChip® FR1, the ClearCell® FX1 System achieves label-free CTC enrichment that better addresses the dynamic and complex nature of cancer.
The wholly intact and viable CTCs isolated using our ClearCell® FX1 System are collected in a liquid suspension and can be transferred to various formats, such as glass slides and microtiter plates, for easy integration with routine pathology laboratory workflows.
122 Emerald Hill Road,
Singapore 229405
Tel: 64820668
sales@ebfholdings.com
support@ebfholdings.com
Read more
